Gapping down
In reaction to disappointing earnings/guidance: CONN -25.5%, VIVO -0.6%.
Select pharma/biotechl related names showing weakness: AMPE -5.1% (announces update on the phase III, multicenter, double-blind STEP study of Ampion for osteoarthritis of the knee), GSK -1.6%, AZN -1.1%.
Select metals/mining stocks trading lower: GFI -2.5%, PAAS -2.4%, NEM -2.1%, GG -2%, GDX -1.8%, SLV -1.7%, GOLD -1.7%, GLD -1.6%, SLW -1.4%, .
Other news: EXEL -52.4% (announces results from the COMET-1 Phase 3 pivotal trial of Cabozantinib in men with metastatic castration-resistant prostate cancer), RIBT -17.4% (disclosed its Irgovel plant experienced a structural breakdown; co withdraws prior guidance), TWGP -11.9% (received a letter from the SEC stating that the SEC is conducting an investigation and attaching a subpoena for various documents), PT -2.7% (still checking), LXRX -1.3% (files for $150 mln mixed securities shelf offering), PXLW -1.2% (files $50 mln common stock shelf offering), HSBC -0.9% (stake sold by Fund Manager Neil Woodford, according to reports), CREE -0.7% (LED demand fell in Q3 QoQ, according to reports (not stock specific)).
Analyst comments: OSIS -3.1% (downgraded to Perform from Outperform at Oppenheimer), FNSR -2.5% (downgraded to Hold from Buy at Jefferies), EMES -1.7% (downgraded to Neutral at Robert W. Baird on valuation), FCX -0.5% (downgraded to Equal-Weight from Overweight).
In reaction to disappointing earnings/guidance: CONN -25.5%, VIVO -0.6%.
Select pharma/biotechl related names showing weakness: AMPE -5.1% (announces update on the phase III, multicenter, double-blind STEP study of Ampion for osteoarthritis of the knee), GSK -1.6%, AZN -1.1%.
Select metals/mining stocks trading lower: GFI -2.5%, PAAS -2.4%, NEM -2.1%, GG -2%, GDX -1.8%, SLV -1.7%, GOLD -1.7%, GLD -1.6%, SLW -1.4%, .
Other news: EXEL -52.4% (announces results from the COMET-1 Phase 3 pivotal trial of Cabozantinib in men with metastatic castration-resistant prostate cancer), RIBT -17.4% (disclosed its Irgovel plant experienced a structural breakdown; co withdraws prior guidance), TWGP -11.9% (received a letter from the SEC stating that the SEC is conducting an investigation and attaching a subpoena for various documents), PT -2.7% (still checking), LXRX -1.3% (files for $150 mln mixed securities shelf offering), PXLW -1.2% (files $50 mln common stock shelf offering), HSBC -0.9% (stake sold by Fund Manager Neil Woodford, according to reports), CREE -0.7% (LED demand fell in Q3 QoQ, according to reports (not stock specific)).
Analyst comments: OSIS -3.1% (downgraded to Perform from Outperform at Oppenheimer), FNSR -2.5% (downgraded to Hold from Buy at Jefferies), EMES -1.7% (downgraded to Neutral at Robert W. Baird on valuation), FCX -0.5% (downgraded to Equal-Weight from Overweight).